BOCA RATON, Fla. — November 25, 2025 — Leads & Copy — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has acquired Liora Technologies Europe Ltd., a UK-based company specializing in electronically controlled proton therapy systems for cancer treatment, the company announced today.
Liora Technologies Europe Ltd. will operate as a wholly-owned subsidiary of LIXTE. The acquisition includes Liora’s flagship LiGHT System (Linac for Image Guided Hadron Therapy) technology, with $300+ million invested to date in developing the technology at the Daresbury site of the UK-based Science and Technology Facilities Council (STFC).
Liora’s LiGHT system is installed at STFC’s Daresbury Laboratory, which will provide resources to develop a center of excellence for proton therapy treatment using the LiGHT system.
Geordan Pursglove, CEO of LIXTE, said the acquisition represents LIXTE’s entry into the radiotherapy segment of cancer care and a significant step in its corporate growth. Pursglove believes that Liora’s LiGHT System has global potential and could become a new gold standard in cancer care by delivering scalable and clinically versatile high-precision proton therapy.
Professor Steve Myers, former Director of Accelerators and Technology at CERN, noted that the LiGHT System delivers high dose rates to deep-seated tumors while reducing installation costs and treatment sessions compared to current technologies. Myers anticipates that the LiGHT System will significantly increase the number of patients a treatment center can serve. He is excited to see how LIXTE advances and scales this technology into a transformative new standard in cancer treatment.
Pursglove said the plan is to bring the LiGHT system to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model through jointly operated treatment centers. Pursglove added that Liora complements the pharmaceutical side of LIXTE’s business and its ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data (see www.lixte.com), LB-100 has the potential to enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
For more information about LIXTE, contact info@lixte.com or General Phone: (631) 830-7092; Investor Phone: (888) 289-5533, or PondelWilkinson Inc. Investor Relations at pwinvestor@pondel.com, Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962.
Source: LIXTE Biotechnology Holdings, Inc.
